Page 581 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

24. ANTPYRIMIDINES 541

MYERS C.E., The pharmacology of the fluoropyrimidines, Pharmac. Rev., 1981, 33, 1-15.
GLOVER A.B., LEYLAND-JONES B.R., Biochemistry of azacytidine: a review, Cancer
Treatment Rep., 1987, 71, 959-964.
DROZ J.P. et al., Handbook of chemotherapy in clinical oncology, FIIS, Paris, 1988.
PARKER W.B., CHENG Y.C., Metabolism and mechanism of action of 5-fluorouracil,
Pharmac. Ther., 1990, 48, 381-395.
LEMAIRE et al., The Tris formulation of fluorouracil is more cardiotoxic than the sodium
sait formulations, Oncology Rep., 1994, 1, 173.
PRATT W.B. et al., The anticancer drugs, Oxford University Press, Oxford, 1994, 69-107.
Alkasar-18 (NOAC), Orugs of the Future, 1995, 20, 11-15.
Fazarabine, Drugs of the Future, 1989, 14, 20 ; 1997, 22, 76.
Capecitabine, Drugs of the Future, 1996, 21, 358-360; 1997, 22, 417-418.
DIASIO R.B., lmproving fluorouracil chemotherapy with nove! orally administered fluoro-
pyrimidines, Drugs, 1999, 58 (suppl. 3), 119-126.
SCHÛLLER J. et al., Preferential activation of capecitabine in tumor following oral admi-
nistration to colorectal cancer patients, Cancer Chemother. Pharmacol., 2000, 45,
291-297.
Decitabine, Orugs of the Future, 1990, 15, 19; 1997, 22, 71; 1998, 23, 84-86 ; 2001, 26,
67-68.